Alec Stranahan
Stock Analyst at B of A Securities
(0.63)
# 3,789
Out of 4,829 analysts
30
Total ratings
35%
Success rate
-32.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $18.34 | +129.01% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.07 | +194.84% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $5.09 | +194.99% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.67 | +274.81% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $0.82 | +1,243.59% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.37 | +264.96% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.49 | +141.45% | 2 | Nov 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $42.11 | +30.61% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $6.42 | +180.59% | 3 | Jun 14, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $140.00 | - | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $8.91 | +371.38% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $35.20 | -82.95% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.27 | +293.67% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $46.14 | -2.46% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $18.34
Upside: +129.01%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.07
Upside: +194.84%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.09
Upside: +194.99%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.67
Upside: +274.81%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $0.82
Upside: +1,243.59%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.37
Upside: +264.96%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.49
Upside: +141.45%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $42.11
Upside: +30.61%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $6.42
Upside: +180.59%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $140.00
Upside: -
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $8.91
Upside: +371.38%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $35.20
Upside: -82.95%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.27
Upside: +293.67%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $46.14
Upside: -2.46%